Logo
x

Search

Subscribe Now

 Nefecon

Everest Medicines Report the NDA Acceptance of Nefecon by the Taiwan FDA for the Treatment of Primary IgA Nephropathy

Everest Medicines Report the NDA Acceptance of Nefecon by the Taiwan FDA for the Treatment of Primary IgA Nephropathy

  • December 27, 2023
Calliditas Therapeutics Reports the US Regulatory Update on Nefecon for the Treatment of IgA Nephropathy

Calliditas Therapeutics Reports the US Regulatory Update on Nefecon for the Treatment of IgA Nephropathy

  • August 21, 2023
Everest Medicines Partner Calliditas Publish P-III (NeflgArd) Trial Results of Nefecon for Primary IgA Nephropathy in The Lancet

Everest Medicines Partner Calliditas Publish P-III (NeflgArd) Trial Results of Nefecon for Primary IgA Nephropathy in The Lancet

  • August 18, 2023
Everest Medicines Reports the Commercial Availability of Xerava (eravacycline) in China

Everest Medicines Reports the Commercial Availability of Xerava (eravacycline) in China

  • July 27, 2023
Singapore HSA Accepts NDA of Everest Medicines’ Nefecon for the Treatment of Primary IgA Nephropathy

Singapore HSA Accepts NDA of Everest Medicines’ Nefecon for the Treatment of Primary IgA Nephropathy

  • April 6, 2023
Calliditas’ Nefecon Meets its Primary Endpoint in P-III Trial (NefIgArd) for the Treatment of IgA Nephropathy

Calliditas’ Nefecon Meets its Primary Endpoint in P-III Trial (NefIgArd) for the Treatment of IgA Nephropathy

  • March 13, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.